Navigation Links
Stereotaxis Epoch™ Solution's Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting

ST. LOUIS, May 7, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ:   STXS) will highlight clinical results from the first 1,250 cases and the latest innovations for the Epoch™ platform, its new generation comprehensive solution for the electrophysiology (EP) laboratory, at the 33rd Annual Heart Rhythm Society (HRS) Scientific Sessions, May 9-12, 2012. 

The formal HRS academic program features multiple invited presentations, podium presentations, and posters detailing Stereotaxis' clinical results in a wide variety of arrhythmias. A total of 11 invited podium presentations feature use of Stereotaxis magnetic navigation technology.   In addition, 13 submitted abstracts that feature or discuss Stereotaxis technology are included in this year's HRS program.  Highlights of these submitted abstracts include comparative data on VT ablation, multi-center VT data, lesion formation, pediatric outcome data, and the first large series of Vdrive™ system's clinical outcomes data.

Stereotaxis will be at booth number 1307, providing demonstrations of commercially available products and a technical suite for obtaining input on new product innovations from select physician customers.  In addition, the Company will feature at the booth a speaker series where customers will share their experiences with the Epoch™ and Odyssey™ product platforms.  In-booth speakers include:

  • Dr. Robert Schweikert from Akron General Medical Center on the Odyssey™ Solution (May 10 at 9:30 am ET);
  • Dr. Yaariv Khaykin from Southlake Regional Health Center on the Odyssey™ Solution (May 10 at 10:00 am ET); and
  • Dr. J. Peter Weiss from Intermountain Medical Center on the Epoch™ Solution (May 10 at 3:45 pm ET and May 11 at 10:00 am ET). 

Stereotaxis will unveil a broad number of product innovations for the Niobe® ES, Vdrive™ and Odyssey™ platforms scheduled to be shipped in 2012.  The innovations include advancements in linear line formation and testing, Vdrive™ offering and Odyssey™ remote collaboration. 

"Stereotaxis will launch exciting advancements at the upcoming HRS congress, which will further enhance the value we bring to the EP market," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  The 2012 innovations for the Niobe® ES and Odyssey™ product platforms as well as the new Vdrive™ platform demonstrate our continued commitment to providing new solutions for the EP market."

About Stereotaxis           

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit and  

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources, including our ability to extend our current loan facility and to obtain additional capital through other financing arrangements, in each case on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis to Report First Quarter 2012 Financial Results on May 8, 2012
2. Stereotaxis Reports 2011 Financial Results; Provides 2012 Milestones
3. Stereotaxis to Report Fourth Quarter and Full Year 2011 Financial Results on March 5, 2012
4. Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers
5. Stereotaxis to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Stereotaxis Reports Third Quarter Financial Results
7. Stereotaxis to Report Third Quarter 2011 Financial Results and Conduct Conference Call on November 7, 2011
8. Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011
9. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
10. Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
11. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
Post Your Comments:
(Date:11/24/2015)... 24. November 2015 Avery Biomedical ... Systems, ist erfreut, die Berufung von Anders ... geben zu können. ... --> Foto -   ... Von 1984-1986 war er Fellow des Cardiovascular ...
(Date:11/24/2015)... India , November 24, 2015 ... market research report "Spine Biologics Market by Product Type (Bone ... (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End ... MarketsandMarkets, the global market was valued at $1.90 Billion in ... at a CAGR of 4.4% during the forecast period of ...
(Date:11/24/2015)... Nov. 24, 2015 Avery Biomedical Devices (ABD), ... to announce the appointment of Anders Jonzon , ... Dr. Jonzon is a ... Children,s Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... was a fellow at the Cardiovascular Institute (UCSF). His ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT ... 3:00 p.m. EST, , FDA has long asserted that design and ... to performing the tests and do not meet the device regulations. , Come up ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... pleased to welcome Winter-Dent & Company as its newest Partner Firm. Based in ... become a client's most trusted advisor regardless of whether that client is a ...
(Date:11/24/2015)... ... ... With Thanksgiving right around the corner, holiday travel season is about to begin. ... vehicle. , According to the National Highway Traffic Safety Administration, 301 people were killed ... safety tips from the NHTSA: , Inspect tires ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey , ... His new venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep ... who have opened a Koala Center for Sleep Disorders in the US, one of four ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Dr. Kevin ... office to help the community stress less this holiday season. During the Indiana ... stress in people's lives and the team at AlignLife want to help provide the ...
Breaking Medicine News(10 mins):